




0590
④

Patent Docket P1134R2C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Avi J. Ashkenazi et al. Serial No.: 09/894,924 Filed: June 28, 2001 For: DcR3 POLYPEPTIDE, A TNFR HOMOLOG	Group Art Unit: To Be Assigned Examiner: To Be Assigned
	<p align="center">CERTIFICATE OF MAILING</p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on</p> <p align="right">July 30, 2001</p> <p align="right"> Eileen Ly</p>

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

☒ **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

☐ **37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

☐ **37 CFR §1.97(d)**

- after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) and a statement as specified in 37 CFR §1.97(e), as checked below.

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

- ☐ **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- ☐ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified).

A copy of the items on PTO-1449 is supplied herewith.

Those patent(s) or publication(s) which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied because they were previously cited by or submitted to the Office in a prior application Serial No. 09/157,289, filed September 18, 1998 and relied upon in this application for an earlier filing date under 35 USC §120.

☐ BLAST results enclosed:

The undersigned also wishes to bring to the attention of the Examiner BLAST results of computerized alignments of the against sequences contained in the nucleotide and protein databases. The BLAST results are provided in paper form and are identified as reference "BLAST Results A-1- A-()" (nucleotide) and "BLAST Results B-1 - B-()" (protein) on the PTO Form 1449. Applicant requests that these references also be considered and that the Form 1449 be initialed to indicate the Examiner's consideration of the references.

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ not given

☐ given for each listed item

☐ given for only non-English language listed item(s) [Required]

☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart

application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

In the event that the Office determines a fee to be due where none is specifically authorized in this paper, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p).

Respectfully submitted,

GENENTECH, INC.

Date: July 30, 2001

By:



Diane L. Marschang

Reg. No. 35,600

Telephone No. (650) 225-5416



09157

PATENT TRADEMARK OFFICE

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1134R2C1

Serial No.

09/894,924

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

28 Jun 2001

Group

To Be Assigned

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	* 1	4,179,337	18.12.79	Davis et al.			
	* 2	4,301,144	17.11.81	Iwashita et al.			
	* 3	4,399,216	16.08.83	Axel et al.			
	* 4	4,496,689	29.01.85	Mitra, G.			
	* 5	4,640,835	03.02.87	Shimizu et al.			
	* 6	4,670,417	02.06.87	Iwasaki et al.			
	* 7	4,676,980	30.06.87	Segal et al.			
	* 8	4,736,866	12.04.88	Leder et al.			
	* 9	4,791,192	13.12.88	Nakagawa et al.			
	* 10	4,816,567	28.03.89	Cabilly et al.			
	* 11	4,870,009	26.09.89	Evans et al.			
	* 12	5,010,182	23.04.91	Brake et al.			
	* 13	5,364,934	15.11.94	Drayna et al.			
	* 14	5,447,851	05.09.95	Beutler et al.			
	* 15	5,885,800	23.03.99	Emery et al.			
	* 16	60/035,496					14.01.97
	* 17	60/035,722					28.01.97
	* 18	60/037,829					05.02.97
	* 19	60/079,856		Dou et al.			30.03.98
	* 20	60/086,074		Dou et al.			20.05.98
	* 21	60/099,643		Dou et al.			09.09.98
	* 22	60/112,577		Dou et al.			17.12.98
	* 23	60/112,703		Dou et al.			18.12.98
	* 24	60/112,933		Dou et al.			18.12.98
	* 25	60/113,407		Dou et al.			22.12.98

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No	
	* 26	0,003,089 A1	25.07.79	EPO (ENGLISH ABSTRACT ATTACHED)				
	* 27	036,776 A2	30.09.81	EPO				
	* 28	073,657	09.03.83	EPO				
	* 29	117,058 A2	29.08.84	EPO				
	* 30	117,060 A2	29.08.84	EPO				
	* 31	307,247 B1	15.03.89	EPO				
	* 32	362,179 A2	04.04.90	EPO				
	* 33	417,563 B1	20.03.91	EPO (ENGLISH ABSTRACT ATTACHED)				

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1134R2C1

Serial No.

09/894,924

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

28 Jun 2001

Group

To Be Assigned

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No	
	* 34	861,850	02.09.98	EPO				
	* 35	19,809,978	16.09.99	GERMANY				
	* 36	WO 00/32221	08.06.00	PCT				
	* 37	WO 00/52028	08.09.00	PCT				
	* 38	WO 00/53758	14.09.00	PCT				
	* 39	WO 00/58465	05.10.00	PCT				
	* 40	WO 00/58466	05.10.00	PCT				
	* 41	WO 87/05330	11.09.87	PCT				
	* 42	WO 89/05859	29.06.89	PCT				
	* 43	WO 90/13646	15.11.90	PCT (ENGLISH ABSTRACT ATTACHED)				
	* 44	WO 91/00360	10.01.91	PCT				
	* 45	WO 92/20373	26.11.92	PCT				
	* 46	WO 93/08829	13.05.93	PCT				
	* 47	WO 97/23614	03.07.97	PCT				
	* 48	WO 97/25428	17.07.97	PCT				
	* 49	WO 98/30694	16.07.98	PCT				
	* 50	WO 98/32856	30.07.98	PCT				
	* 51	WO 99/04001	28.01.99	PCT				
	* 52	WO 99/07738	18.02.99	PCT				
	* 53	WO 99/11791	11.03.99	PCT				
	* 54	WO 99/14330	25.03.99	PCT				
	* 55	WO 99/26977	03.06.99	PCT				
	* 56	WO 99/31128	24.06.99	PCT				
	* 57	WO 99/50413	10.07.99	PCT				
	* 58	2,211,504	05.07.89	UNITED KINGDOM				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	* 59	Altschul et al., "Local alignment statistics" <u>Methods in Enzymology</u> 266:460-480 (1996)
	* 60	Amakawa et al., "The Hodgkin Disease Antigen CD30 is Crucial for Antigen-induced Death of Developing T Cells" <u>Cold Spring Harbor Laboratory Symposium on Programmed Cell Death</u> (Abstr. No. 10) (1995)
	* 61	Anderson et al., "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function" <u>Nature</u> 390(6656):175-179 (Nov 13, 1997)
	* 62	Anderson, W.F., "Human gene therapy" <u>Science</u> 256(5058):808-813 (May 8, 1992)
	* 63	Aplin and Wriston, "Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids" <u>CRC Crit. Rev. Biochem.</u> 10(4):259-306 (1981)
	* 64	Arase et al., "Fas-mediated cytotoxicity by freshly isolated natural killer cells" <u>Journal of Experimental Medicine</u> 181(3):1235-1238 (Mar 1, 1995)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1134R2C1

Serial No.

09/894,924

Applicant

Ashkenazi et al.

Filing Date

28 Jun 2001

Group

To Be Assigned

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

* 65	Ashkenazi and Chamow, "Immunoadhesins: An Alternative to Human Monoclonal Antibodies" <u>Methods: A Companion to Methods in Enzymology</u> 8:104-115 (1995)
* 66	Ashkenazi et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin" <u>Proc. Natl. Acad. Sci.</u> 88:10535-10539 (1991)
* 67	Bai et al., "Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster" <u>Proc. Natl. Acad. Sci.</u> 97:1230-1235 (2000)
* 68	Banner et al., "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNF β Complex: Implications for TNF Receptor Activation" <u>Cell</u> 73:431-445 (1993)
* 69	Bodmer et al., "TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)" <u>Immunity</u> 6:79-88 (1997)
* 70	Boerner et al., "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes" <u>The Journal of Immunology</u> 147(1):86-95 (1991)
* 71	Bolivar et al., "Construction and Characterization of New Cloning Vehicles. II. A Multipurpose Cloning System" <u>Gene</u> 2:95-113 (1977)
* 72	Bradley, "Production and Analysis of Chimaeric Mice" <u>Teratocarcinomas and Embryonic Stem Cells: A Practical Approach</u> , E. J. Robertson, ed., IRL, Oxford, Chapter 5, pps. 113-151 (1987)
* 73	Brockhaus et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies" <u>Proc. Natl. Acad. Sci. USA</u> 87:3127-3131 (1990)
* 74	Brodeur et al., "Mouse-Human Myeloma Partners for the Production of Heterohybridomas" <u>Monoclonal Antibody Production Techniques and Applications</u> , New York:Marcel Dekker, Inc. pps. 51-63 (1987)
* 75	Brojatsch et al., "CAR1, a TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis" <u>Cell</u> 87:845-855 (1996)
* 76	Carter et al., "Improved oligonucleotide site-directed mutagenesis using M13 vectors" <u>Nucl. Acids Res.</u> 13(12):4431-4443 (1985)
* 77	Chang et al., "Phenotypic Expression in E. coli of a DNA Sequence Coding for Mouse Dihydrofolate Reductase" <u>Nature</u> 275:617-624 (October 19, 1978)
* 78	<u>Chemotherapy Service Ed.</u> , M.C. Perry, Baltimore, MD:Williams & Wilkins (1992)
* 79	Chicheportiche et al., "TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis" <u>Journal of Biological Chemistry</u> 272(51):32401-32410 (1997)
* 80	Chinnaiyan et al., "Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95" <u>Science</u> 274:990-992 (1996)
* 81	Chothia, "The Nature of the Accessible and Buried Surfaces in Proteins" <u>Journal Mol. Biol.</u> 105:1-14 (1976)
* 82	Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" <u>Monoclonal Antibodies and Cancer Therapy</u> , New York:Alan R. Liss, Inc. pps. 77-96 (1985)
* 83	Coligan et al. <u>Current protocols in immunology</u> , New York:John Wiley & Sons (1994)
* 84	Creighton,, "Protein Biosynthesis" <u>Proteins: Structures and Molecular Principles</u> , San Francisco:W.H. Freeman & Co. pps. 79-86 (1983)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1134R2C1

Serial No.

09/894,924

Applicant

Ashkenazi et al.

Filing Date

28 Jun 2001

Group

To Be Assigned

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

* 85	David et al., "Protein Iodination with Solid State Lactoperoxidase" <u>Biochemistry</u> 13(5):1014-1021 (1974)
* 86	Dealtry et al., "DNA Fragmentation and Cytotoxicity Caused by Tumor Necrosis Factor is Enhanced by Interferon- γ " <u>European Journal of Immunology</u> 17:689-693 (1987)
* 87	deBoer et al., "The TAC Promoter: A functional Hybrid Derived From the TRP and LAC Promoters" <u>Proc. Natl. Acad. Sci. USA</u> 80:21-25 (1983)
* 88	Deutscher, M., "Rethinking your purification procedure" <u>Methods in Enzymology</u> 182:779-780 (1990)
* 89	Dhein et al., "Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)" <u>Nature</u> 373(6513):438-441 (Feb 2, 1995)
* 90	Dieffenbach et al., <u>PCR Primer: A Laboratory Manual</u> , Cold Spring Harbor Laboratory Press (1995)
* 91	Dzau et al., "Gene therapy for cardiovascular disease" <u>Trends in Biotechnology</u> 11:205-210 (1993)
* 92	Edge et al., "Deglycosylation of glycoproteins by trifluoromethanesulfonic acid" <u>Analytical Biochemistry</u> 118:131-137 (1981)
* 93	Evan et al., "Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product" <u>Molecular & Cellular Biology</u> 5:3610-3616 (1985)
* 94	Field et al., "Purification of a RAS-Responsive Adenylyl Cyclase Complex from <i>Saccharomyces cerevisiae</i> by Use of an Epitope Addition Method" <u>Molecular & Cellular Biology</u> 8:2159-2165 (1988)
* 95	Gelb et al., "Pycnodysostosis: Refined Linkage and Radiation Hybrid Analyses Reduce the Critical Region to 2 cM at 1q21 and Map Two Candidate Genes" <u>Human Genet.</u> 98:141-144 (1996)
* 96	Gelmini et al., "Quantitative polymerase chain reaction-based homogeneous assay with fluorogenic probes to measure c-erbB-2 oncogene amplification" <u>Clinical Chemistry</u> 43(5):752-758 (May 1997)
* 97	Gething and Sambrook, "Cell-surface Expression of Influenza Haemagglutinin from a Cloned DNA Copy of the RNA Gene" <u>Nature</u> 293:620-625 (October 22, 1981)
* 98	Goding, "Production of Monoclonal Antibodies" <u>Monoclonal Antibodies: Principles and Practice</u> , Academic Press, pps. 59-103 (1986)
* 99	Goeddel et al., "Direct Expression in <i>Escherichia coli</i> of a DNA Sequence Coding for Human Growth Hormone" <u>Nature</u> 281:544-548 (October 18, 1979)
*100	Goeddel et al., "Synthesis of Human Fibroblast Interferon by <i>E. coli</i> " <u>Nucleic Acids Research</u> 8(18):4057-4074 (1980)
*101	Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor" <u>Molecular & Cellular Biology</u> 11:3020-3026 (1991)
*102	Graham and van der Eb, "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA" <u>Virology</u> 52:456-467 (1973)
*103	Graham et al., "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5" <u>J. Gen. Virol.</u> 36:59-74 (1977)
*104	Gruss and Dower, "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas" <u>Blood</u> 85:3378-3404 (1995)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1134R2C1

Serial No.

09/894,924

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

28 Jun 2001

Group

To Be Assigned

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*105	Hahne et al., "Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape" <u>Science</u> 274(5291):1363-1366 (Nov 22, 1996)
*106	Hale et al., "Demonstration of in vitro and in vivo efficacy of two biologically active human soluble TNF receptors expressed in E. coli" <u>J. Cell. Biochem.</u> (abstract only Supplement 15F; P 424) pps. 113 (1991)
*107	<u>Handbook of Monoclonal Antibodies</u> , Ferrone et al. eds., Park Ridge, NJ:Noyes Publications, pps. 302-359 and Chapter 22 (1985)
*108	Hess et al., "Cooperation of Glycolytic Enzymes" <u>Advances in Enzyme Regulation</u> , George Weber, New York:Pergamon Press Vol. 7:149-167 (1968)
*109	Hitzeman et al., "Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an Immunological Screening Technique" <u>Journal of Biological Chemistry</u> 255(24):12073-12080 (December 25, 1980)
*110	Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNF α)" <u>Journal of Biological Chemistry</u> 264(25):14927-14934 (1989)
*111	Holland and Holland, "Isolation and Identification of Yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceraldehyde-3-phosphate Dehydrogenase, and Phosphoglycerate Kinase" <u>Biochemistry</u> 17(23):4900-4907 (1978)
*112	Holmes et al., "Structure and Functional Expression of a Human Interleukin-8 Receptor" <u>Science</u> 253(5025):1278-1280 (1991)
*113	Hoogenboom and Winter, "By-passing immunisation: human antibodies from synthetic repertoires of germline V _H gene segments rearranged in vitro" <u>J. Mol. Biol.</u> 227:381-388 (1992)
*114	Hopp et al., "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification" <u>Bio/Technology</u> 6:1204-1210 (1988)
*115	Hsiao and Carbon, "High-frequency Transformation of Yeast by Plasmids Containing the Cloned Yeast Arg4 Gene" <u>Proc. Natl. Acad. Sci. USA</u> 76:3829-3833 (1979)
*116	Hunter et al., "Preparation of Iodine 131 Labelled Human Growth Hormone of High Specific Activity" <u>Nature</u> 194:495-496 (1962)
*117	Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis" <u>Cell</u> 66:233-243 (1991)
*118	Johnson et al., "Expression and Structure of the Human NGF Receptor" <u>Cell</u> 47:545-554 (1986)
*119	Jones et al., "Replacing the Complementarity-determining Regions in a Human Antibody with Those From a Mouse" <u>Nature</u> 321:522-525 (May 29, 1986)
*120	Jones, E., "Proteinase Mutants of <i>Saccharomyces Cerevisiae</i> " <u>Genetics</u> 85(1):23-33 (1977)
*121	Keown et al., "Methods for Introducing DNA into Mammalian Cells" <u>Methods in Enzymology</u> 185:527-537 (1990)
*122	Kingsman et al., "Replication in <i>Saccharomyces Cerevisiae</i> of Plasmid pBR313 Carrying DNA from the Yeast trp1 Region" <u>Gene</u> 7:141-152 (1979)
*123	Kitson et al., "A Death-Domain-Containing Receptor that Mediates Apoptosis" <u>Nature</u> 384:372-375 (1996)
*124	Kohler and Milstein, "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity" <u>Nature</u> 256:495-497 (August 7, 1975)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1134R2C1

Serial No.

09/894,924

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

28 Jun 2001

Group

To Be Assigned

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*125	Kohno et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor" <u>Proc. Natl. Acad. Sci. USA</u> 87:8331-8335 (1990)
*126	Kozbor et al., "A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies" <u>The Journal of Immunology</u> 133(6):3001-3005 (1984)
*127	Krammer et al., "Regulation of Apoptosis in the Immune System" <u>Curr. Op. Immunol.</u> 6:279-289 (1994)
*128	Kwon et al., "Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer" <u>Proc. Natl. Acad. Sci. USA</u> 94(15):8099-8103 (Jul 22, 1997)
*129	Lacey et al., "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation" <u>Cell</u> 93(2):165-176 (Apr 17, 1998)
*130	Leach et al., "Enhancement of antitumor immunity by CTLA-4 blockade" <u>Science</u> 271(5256):1734-1736 (Mar 22, 1996)
*131	Lewis et al., "Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific" <u>Proc. Natl. Acad. Sci. USA</u> 88:2830-2834 (1991)
*132	Li et al., "Targeted mutation of the DNA methyltransferase gene results in embryonic lethality" <u>Cell</u> 69:915-926 (1992)
*133	Loetscher et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor" <u>Cell</u> 61:351-359 (1990)
*134	Lutz-Freyermuth et al., "Quantitative Determination That One of Two Potential RNA-binding Domains of the A Protein Component of the U1 Small Nuclear Ribonucleoprotein Complex Binds with High Affinity to Stem-loop II of U1 RNA" <u>Proc. Natl. Acad. Sci. USA</u> 87:6393-6397 (1990)
*135	Mallett et al., "Characterization of the MRC OX40 Antigen of Activated CD4 Positive T Lymphocytes - a Molecule Related to Nerve Growth Factor Receptor" <u>EMBO Journal</u> 9:1063-1068 (1990)
*136	<u>Mammalian Cell Biotechnology: A Practical Approach</u> , M. Butler, ed., IRL Press (1991)
*137	Mansour et al., "Disruption of the Proto-oncogene int-2 in Mouse Embryo-derived Stem Cells: a General Strategy for Targeting Mutations to Non-selectable Genes" <u>Nature</u> 336:348-352 (1988)
*138	Mantel et al., "Rabbit β -globin mRNA Production in Mouse L Cells Transformed with Cloned Rabbit β -globin Chromosomal DNA" <u>Nature</u> 281:40-46 (September 6, 1979)
*139	Marks et al., "By-passing immunization: human antibodies from V-gene libraries displayed on phage" <u>J. Mol. Biol.</u> 222:581-597 (1991)
*140	Marsters et al., "Activation of Apoptosis by Apo-2 Ligand is Independent of FADD but Blocked by CrmA" <u>Current Biology</u> 6(6):750-752 (1996)
*141	Marsters et al., "Apo-3, a New Member of the Tumor Necrosis Factor Receptor Family, Contains a Death Domain and Activates Apoptosis and NF- κ B" <u>Curr. Biol.</u> 6(12):1669-1676 (1996)
*142	Marsters et al., "Herpesvirus Entry Mediator, A Member of the Tumor Necrosis Factor (TNFR) Family, Interacts with Members of the TNFR-associated Factor Family and Activates the Transcription Factors NF- κ B and AP-1" <u>Journal of Biological Chemistry</u> 272(22):14029-14032 (1997)
*143	Marsters et al., "Identification of a ligand for the death-domain-containing receptor Apo3" <u>Current Biology</u> 8(9):525-528 (1998)
*144	Martin et al., "GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K ⁺ Channel Currents" <u>Science</u> 255:192-194 (1992)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1134R2C1

Serial No.

09/894,924

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

28 Jun 2001

Group

To Be Assigned

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*145	Mather, J.P., "Establishment and Characterization of Two Distinct Mouse Testicular Epithelial Cell Lines" <u>Biol. Reprod.</u> 23:243-252 (1980)
*146	Mauri et al., "LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator" <u>Immunity</u> 8(1):21-30 (Jan 1998)
*147	Medvedev et al., "Regulation of Fas and Fas-ligand expression in NK cells by cytokines and the involvement of Fas- ligand in NK/LAK cell-mediated cytotoxicity" <u>Cytokine</u> 9(6):394-404 (Jun 1997)
*148	Merrifield, R.B., "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide" <u>J. Am. Chem. Soc.</u> 85:2149-2154 (1963)
*149	Milstein et al., "Hybrid Hybridomas and Their Use in Immunohistochemistry" <u>Nature</u> 305:537-540 (1983)
*150	Montgomery et al., "Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family" <u>Cell</u> 87(3):427-436 (1996)
*151	Moretta, A., "Molecular mechanisms in cell-mediated cytotoxicity" <u>Cell</u> 90(1):13-18 (Jul 11, 1997)
*152	Munson et al., "LIGAND: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems" <u>Analytical Biochemistry</u> 107:220-239 (1980)
*153	Nagata and Golstein, "The Fas Death Factor" <u>Science</u> 267:1449-1456 (1995)
*154	Nagata, S., "Apoptosis by Death Factor" <u>Cell</u> 88:355-365 (1997)
*155	Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor" <u>EMBO Journal</u> 9:3269-3278 (1990)
*156	Nygren, H., "Conjugation of Horseradish Peroxidase to Fab Fragments with Different Homobifunctional and Heterobifunctional Cross-Linking Reagents" <u>The Journal of Histochemistry and Cytochemistry</u> 30(5):407-412 (1982)
*157	O'Reilly, D. <u>Baculovirus expression vectors: a laboratory manual</u> , New York:Oxford University Press (1994)
*158	Otsuki et al., "Over-expression of the decoy receptor 3 (Dcr3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients" <u>Clin. Exp. Immunol.</u> 119:323-327 (2000)
*159	Paborsky et al., "Mammalian Cell Transient Expression of Tissue Factor for the Production of Antigen" <u>Protein Eng.</u> 3(6):547-553 (1990)
*160	Pain et al., "Preparation of Protein A-Peroxidase Monoconjugate Using a Heterobifunctional Reagent, and its Use in Enzyme Immunoassays" <u>Journal of Immunological Methods</u> 40:219-230 (1981)
*161	Pan et al., "An Antagonist Decoy Receptor and a Death-domain Containing Receptor for TRAIL" <u>Science</u> 277:815-818 (1997)
*162	Pan et al., "The Receptor for the Cytotoxic Ligand TRAIL" <u>Science</u> 276:111-113 (1997)
*163	Peetre et al., "A tumor necrosis factor binding protein is present in human biological fluids" <u>European Journal of Haematology</u> 41:414-419 (1988)
*164	Pennica et al., "Human Tumour Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin" <u>Nature</u> 312:724-729 (1984)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1134R2C1

Serial No.

09/894,924

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

28 Jun 2001

Group

To Be Assigned

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*165	Pitti et al., "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family" <u>Journal of Biological Chemistry</u> 271:12687-12690 (1996)
*166	Presta, L., "Antibody Engineering" <u>Curr. Op. Struct. Biol.</u> 2:593-596 (1992)
*167	Radeke et al., "Gene transfer and molecular cloning of the rat nerve growth factor receptor" <u>Nature</u> 325:593-597 (1987)
*168	<u>Remington's Pharmaceutical Sciences</u> , Oslo et al., eds., 16th edition, Mack Publishing Co. (1980)
*169	Riechmann et al., "Reshaping Human Antibodies for Therapy" <u>Nature</u> 332:323-327 (Mar 24, 1988)
*170	Ruppert et al., "Cloning and Expression of Human TAF _{II} 250: a TBP-associated Factor Implicated in Cell-cycle Regulation" <u>Nature</u> 362:175-179 (1993)
*171	Sambrook et al. <u>Molecular Cloning: A Laboratory Manual</u> , Second edition, New York: Cold Spring Harbor Laboratory Press (1989)
*172	Samter et al. <u>Samter's Immunological Diseases</u> , 5th edition, Boston: Little, Brown and Company Vol. I & II (1995)
*173	Schall et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor" <u>Cell</u> 61:361-370 (1990)
*174	Schmid et al., "DNA Fragmentation: Manifestation of Target Cell Destruction Mediated by Cytotoxic T-cell Lines, Lymphotoxin-secreting Helper T-cell Clones, and Cell-free Lymphotoxin-containing Supernatant" <u>Proc. Natl. Acad. Sci. USA</u> 83:1881-1885 (1986)
*175	Scopes, R. <u>Protein Purification</u> , New York: Springer-Verlag (1982)
*176	Seckinger et al., "Purification and biologic characterization of a specific tumor necrosis factor α Inhibitor" <u>Journal of Biological Chemistry</u> 264:11966-11973 (1989)
*177	Shaw et al., "A General Method for the Transfer of Cloned Genes to Plant Cells" <u>Gene</u> 23:315-330 (1983)
*178	Sheridan et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors" <u>Science</u> 277:818-821 (1997)
*179	Simonet et al., "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density" <u>Cell</u> 89:309-319 (1997)
*180	Skinner et al., "Use of the Glu-Glu-Phe C-terminal Epitope for Rapid Purification of the Catalytic Domain of Normal and Mutant ras GTPase-activating Proteins" <u>Journal of Biological Chemistry</u> 266:14163-14166 (1991)
*181	Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins" <u>Science</u> 248:1019-1023 (1990)
*182	Smith et al., "Cardiac Glycoside-Specific Antibodies in the Treatment of Digitalis Intoxication" <u>Antibodies in Human Diagnosis and Therapy</u> pps. 365-389 (1977)
*183	Smith et al., "T2 Open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor" <u>Biochem. & Biophys. Res. Comm.</u> 176:335-342 (1991)
*184	Sojar et al., "A Chemical Method for the Deglycosylation of Proteins" <u>Archives of Biochemistry & Biophysics</u> 259(1):52-57 (1987)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1134R2C1

Serial No.

09/894,924

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

28 Jun 2001

Group

To Be Assigned

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*185	Sompayrac et al., "Efficient infection of monkey cells with DNA of simian virus 40" <u>Proc. Natl. Acad. Sci. USA</u> 78(12):7575-7578 (Dec 1981)
*186	Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas" <u>EMBO Journal</u> 8(5):1403-1410 (1989)
*187	Stewart et al. <u>Solid-Phase Peptide Synthesis</u> , San Francisco, CA:W.H. Freeman Co. (1969)
*188	Stinchcomb et al., "Isolation and Characterisation of a Yeast Chromosomal Replicator" <u>Nature</u> 282:39-43 (November 1, 1979)
*189	Strand et al., "Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells --a mechanism of immune evasion?" <u>Nature Medicine</u> 2(12):1361-1366 (Dec 1996)
*190	Suda et al., "Molecular Cloning and Expression of the Fas Ligand, a Novel Member of the Tumor Necrosis Factor Family" <u>Cell</u> 75:1169-1178 (1993)
*191	Suresh et al., "Bispecific Monoclonal Antibodies from Hybrid Hybridomas" <u>Methods in Enzymology</u> 121:210-228 (1986)
*192	Takao et al., "Novel DNA Polymorphism in the Mouse Tumor Necrosis Factor Receptors Type 1 and Type 2" <u>Immunogenetics</u> 37:199-203 (1993)
*193	Thimmappaya et al., "Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection" <u>Cell</u> 31(3 Pt 2):543-551 (Dec 1982)
*194	Thomas and Capecchi, "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells" <u>Cell</u> 51:503-512 (1987)
*195	Thomas, P., "Hybridization of Denatured RNA and Small DNA Fragments Transferred to Nitrocellulose" <u>Proc. Natl. Acad. Sci. USA</u> 77(9):5201-5205 (September 1980)
*196	Thotakura and Bahl, "Enzymatic Deglycosylation of Glycoproteins" <u>Meth. Enzymol.</u> 138:350-359 (1987)
*197	Trautnecker et al., "Bispecific Single Chain Molecules (Janusins) Target Cytotoxic Lymphocytes on HIV Infected Cells" <u>EMBO Journal</u> 10(12):3655-3659 (1991)
*198	Tschumper and Carbon, "Sequence of a Yeast DNA Fragment Containing a Chromosomal Replicator and the TRP1 Gene" <u>Gene</u> 10:157-166 (1980)
*199	Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence" <u>Virology</u> 184:370-382 (1991)
*200	Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region of the Shope fibroma virus genome" <u>Virology</u> 160:20-30 (1987)
*201	Urlaub and Chasin, "Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity" <u>Proc. Natl. Acad. Sci. USA</u> 77(7):4216-4220 (July 1980)
*202	Van Solingen et al., "Fusion of Yeast Spheroplasts" <u>J. Bact.</u> 130:946-947 (1977)
*203	Verhoeven et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" <u>Science</u> 239:1534-1536 (Mar 25, 1988)
*204	Wagner et al., "Transferrin-polycation conjugates as carriers for DNA uptake into cells" <u>Proc. Natl. Acad. Sci.</u> 87:3410-3414 (1990)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Dept. of Commerce
Patent and Trademark Office

P1134R2C1

09/894,924

Applicant

Ashkenazi et al.

Filing Date

28 Jun 2001

Group	Mean	SD	95% CI
Control	1.00	0.00	1.00
Low	1.00	0.00	1.00
High	1.00	0.00	1.00

To Be Assigned

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- | | |
|------|--|
| *205 | Welcher et al., "Nerve growth factor binding domain of the nerve growth factor receptor" <u>Proc. Natl. Acad. Sci. USA</u> 88:159-163 (1991) |
| *206 | Wells et al., "Cassette Mutagenesis: an Efficient Method for Generation of Multiple Mutations at Defined Sites" <u>Gene</u> 34(2-3):315-323 (1985) |
| *207 | Wells et al., "Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin" <u>Philos. Trans. R. Soc. London Ser A</u> 317:415-423 (1986) |
| *208 | Wiley et al., "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis" <u>Immunity</u> 3:673-682 (1995) |
| *209 | Wong et al., "TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells" <u>Journal of Biological Chemistry</u> 272(40):25190-25194 (Oct 3, 1997) |
| *210 | Wu et al., "Receptor-mediated in vitro gene transformation by a soluble DNA carrier system" <u>Journal of Biological Chemistry</u> 262(10):4429-4432 (1987) |
| *211 | Yan and Chao, "Disruption of Cysteine-rich repeats of the p75 nerve growth factor receptor leads to loss of ligand binding" <u>Journal of Biological Chemistry</u> 266:12099-12104 (1991) |
| *212 | Yonehara et al., "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor" <u>Journal of Experimental Medicine</u> 169:1747-1756 (1989) |
| *213 | Yu, K. et al., "A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses light-mediated apoptosis" <u>J. Biol. Chemistry</u> 274(20):13733-13736 (1999) |
| *214 | Zamecnik et al., "Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA" <u>Proc. Natl. Acad. Sci.</u> 83:4143-4146 (1986) |
| *215 | Zheng et al., "Induction of Apoptosis in Mature T Cells by Tumor Necrosis Factor" <u>Nature</u> 377:348-351 (1995) |
| *216 | Zola, "Using Monoclonal Antibodies: Soluble Antigens" <u>Monoclonal Antibodies: A Manual of Techniques</u> , CRC Press, Chapter 6, pps. 147-158 (1987) |
| *217 | Zoller and Smith, "Oligonucleotide-directed Mutagenesis Using M13-derived Vectors: An Efficient and General Procedure for the Production of Point Mutations in Any Fragment of DNA" <u>Nucl. Acids Res.</u> 10(20):6487-6500 (1982) |

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.